|
127 Companies |
|
139 Products |
|
139 Products |
|
89 Mechanisms of Action |
|
9 Trials |
|
1220 News |
|
| «12...13141516171819202122232425» |
- Trial termination: Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=23, Terminated, Sponsor: Columbia University
Recruiting --> Terminated; Poor Enrollment
- Enrollment change: Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=23, Terminated, Sponsor: Columbia University
Recruiting --> Terminated; Poor Enrollment N=200 --> 23
- || Trial completion: Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (clinicaltrials.gov) - Jun 26, 2012
P3, N=33, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
N=200 --> 23 Active, not recruiting --> Completed
- ||||||| Trial completion: Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (clinicaltrials.gov) - Jun 26, 2012
P3, N=85, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- TKM-PLK1 / Arbutus
Enrollment change, Lipid Nanoparticle: TKM 080301 for Primary or Secondary Liver Cancer (clinicaltrials.gov) - Jun 22, 2012
P1, N=1, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=54 --> 1
- TKM-PLK1 / Arbutus
Trial completion, Lipid Nanoparticle: TKM 080301 for Primary or Secondary Liver Cancer (clinicaltrials.gov) - Jun 22, 2012
P1, N=1, Completed, Sponsor: National Cancer Institute (NCI)
N=54 --> 1 Recruiting --> Completed
- | docetaxel / Generic mfg., epirubicin / Generic mfg.
New P2 trial: A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin (clinicaltrials.gov) - Jun 18, 2012
P2, N=60, Recruiting, Sponsor: Yonsei University
- | New P4 trial, Surgery: Fast-track Surgery for Perforated Peptic Ulcers (clinicaltrials.gov) - Jun 13, 2012
P4, N=61, Completed, Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- golvatinib (E7050) / Eisai
Enrollment change, Combination therapy, Metastases: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer (clinicaltrials.gov) - Jun 11, 2012
P1/2, N=7, Terminated, Sponsor: Eisai Inc.
Recruiting --> Completed N=95 --> 7
- irinotecan / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus (clinicaltrials.gov) - Jun 11, 2012
P2, N=61, Completed, Sponsor: Southwest Oncology Group
N=95 --> 7 Active, not recruiting --> Completed
- Clinical: Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric Cancer (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=282, Completed, Sponsor: Peking Union Medical College Hospital
- varlitinib (ASLAN001) / ASLAN Pharma
New P2 trial, Metastases: A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 (clinicaltrials.gov) - Jun 6, 2012
P2, N=24, Completed, Sponsor: Aslan Pharmaceuticals
- Trial completion: Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible? (clinicaltrials.gov) - Jun 4, 2012
P4, N=200, Completed, Sponsor: Ruttonjee Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
New P1/2 trial: Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer (clinicaltrials.gov) - Jun 3, 2012
P1/2, N=1, Terminated, Sponsor: Dr Anna Dorothea Wagner
- ||||||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: EXPAND: Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (clinicaltrials.gov) - May 29, 2012
P3, N=904, Completed, Sponsor: Merck KGaA
Recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis (clinicaltrials.gov) - May 28, 2012
P2, N=50, Completed, Sponsor: Martin-Luther-Universit
- Enrollment change, IO biomarker, Metastases: Laparoscopic Gastrectomy for Advanced Gastric Cancer (clinicaltrials.gov) - May 20, 2012
P2, N=200, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed N=300 --> 200
- Enrollment closed, IO biomarker, Metastases: Laparoscopic Gastrectomy for Advanced Gastric Cancer (clinicaltrials.gov) - May 20, 2012
P2, N=200, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
N=300 --> 200 Recruiting --> Active, not recruiting
- ||||| camicinal (GSK962040) / GSK
New P2 trial: A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying (clinicaltrials.gov) - May 17, 2012
P2, N=70, Recruiting, Sponsor: GlaxoSmithKline
- New P3 trial: Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial (clinicaltrials.gov) - May 16, 2012
P3, N=30, Completed, Sponsor: University of Alberta
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - May 14, 2012
P2, N=41, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, IO biomarker: NCC052: Clinical Study on Laparoscopic Gastrectomy for Early Gastric Cancer (COACT_0301) (clinicaltrials.gov) - May 9, 2012
P3, N=164, Completed, Sponsor: National Cancer Center, Korea
Active, not recruiting --> Completed Recruiting --> Completed
- | esomeprazole / Generic mfg.
New P4 trial: The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers (clinicaltrials.gov) - May 1, 2012
P4, N=300, Recruiting, Sponsor: National Cheng-Kung University Hospital
- ||||| onartuzumab (RG3638) / Roche
New P2 trial, Combination therapy, Metastases: A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer (clinicaltrials.gov) - May 1, 2012
P2, N=123, Active, not recruiting, Sponsor: Hoffmann-La Roche
- Enrollment change: Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders (clinicaltrials.gov) - Apr 30, 2012
P=N/A, N=400, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=300 --> 400
- aspirin / Generic mfg.
Clinical: Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=904, Completed, Sponsor: Chinese University of Hong Kong
- Trial completion: Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia (clinicaltrials.gov) - Apr 20, 2012
P=N/A, N=126, Completed, Sponsor: Konyang University Hospital
N=300 --> 400 Recruiting --> Completed
- Enrollment change: Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=2000, Recruiting, Sponsor: Odense University Hospital
Recruiting --> Completed N=3500 --> 2000
- HEOR: A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=75, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- ||||| New P2 trial: Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis (clinicaltrials.gov) - Apr 15, 2012
P2, N=102, Completed, Sponsor: SK Chemicals Co.,Ltd.
- Enrollment change: Comparison of Standard of Care or Treatment on Protocol (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
N=3500 --> 2000 N=2000 --> 13
- | Enrollment open, Surgery, Biopsy: Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer (clinicaltrials.gov) - Apr 11, 2012
P3, N=160, Recruiting, Sponsor: National Cancer Center, Korea
N=2000 --> 13 Not yet recruiting --> Recruiting
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial, Metastases: A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients (clinicaltrials.gov) - Apr 10, 2012
P2, N=11, Completed, Sponsor: Novartis Pharmaceuticals
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Surgery, Metastases: SAKK 43/99: Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer (clinicaltrials.gov) - Apr 9, 2012
P3, N=240, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | New P4 trial: Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor (clinicaltrials.gov) - Apr 4, 2012
P4, N=100, Not yet recruiting, Sponsor: Gachon University Gil Medical Center
- ||||| relamorelin (RM-131) / AbbVie
New P2 trial: Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis (clinicaltrials.gov) - Apr 3, 2012
P2, N=185, Active, not recruiting, Sponsor: Rhythm Pharmaceuticals, Inc.
- lapatinib / Generic mfg.
Trial completion, Metastases: S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Gastric vs Jejunal Feeding in Diabetic Gastroparesis (clinicaltrials.gov) - Apr 1, 2012
P4, N=0, Withdrawn, Sponsor: University of Zurich
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Gastric vs Jejunal Feeding in Diabetic Gastroparesis (clinicaltrials.gov) - Apr 1, 2012
P4, N=0, Withdrawn, Sponsor: University of Zurich
Not yet recruiting --> Withdrawn N=12 --> 0
- |||| 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: NEOTAX: Docetaxel in Locally Advanced Gastric Adenocarcinoma (clinicaltrials.gov) - Apr 1, 2012
P2, N=59, Completed, Sponsor: Sanofi
N=12 --> 0 Active, not recruiting --> Completed
- ||| Voquezna (vonoprazan) / Takeda, Phathom Pharma
New P3 trial: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy (clinicaltrials.gov) - Mar 29, 2012
P3, N=27, Completed, Sponsor: Takeda
- ||| Voquezna (vonoprazan) / Takeda, Phathom Pharma
New P3 trial: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy (clinicaltrials.gov) - Mar 29, 2012
P3, N=30, Completed, Sponsor: Takeda
- ||| Trial completion: EVOLUTION (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=110, Completed, Sponsor: Cook
Active, not recruiting --> Completed Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Enrollment open: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion, Metastases: SAKK 42/99: Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer (clinicaltrials.gov) - Mar 25, 2012
P2, N=0, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- relamorelin (RM-131) / AbbVie
Enrollment change: Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis (clinicaltrials.gov) - Mar 22, 2012
P1, N=20, Completed, Sponsor: Rhythm Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=10 --> 20
- Enrollment change: GIVTE: Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=285, Completed, Sponsor: University of Aarhus
N=10 --> 20 N=150 --> 285
- Trial completion: GIVTE: Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=285, Completed, Sponsor: University of Aarhus
N=150 --> 285 Recruiting --> Completed
- | camicinal (GSK962040) / GSK
Enrollment change: The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis (clinicaltrials.gov) - Mar 21, 2012
P2, N=11, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=18 --> 11
- Enrollment closed, Metastases: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach (clinicaltrials.gov) - Mar 21, 2012
P2, N=61, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=18 --> 11 Recruiting --> Active, not recruiting